Censored/Censoring of Data
An observation is said to be censored in time when the event of interest cannot be observed at the time at which the analysis isconducted.
An observation is said to be censored in time when the event of interest cannot be observed at the time at which the analysis isconducted.
The evaluation of the likelihood that a medicine was the causative agent of an observed adverse event in a specific individual. Causality assessment is usually
A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject.Source:
A person who helps a patient with daily activities, healthcare, or other activities that the patient is unable to perform because of age, illness or
A study that evaluates the association of specific genetic variants with outcomes or traits of interest, selecting the variants to be tested according to explicit
Samarind Strengthens Ennov’s global position in the RIM for Medical Devices and its presence in the UK market Ennov, a leading provider of regulated content
Pharmacovigilance Webinar PV Made Simple: Discover a Fully Compliant AND Affordable Solution in Just 30 Minutes Streamline processes and break down silos to reduce time
The Quality Management System (QMS) landscape is continually transforming, driven by innovative technologies and emerging trends. Discover the essential insights from Gartner’s latest Market Guide
Maximize your regulatory team’s potential with a right-sized RIM. Learn how SMBs can bring products to market faster with fewer resources.
Effortlessly build, manage, and publish regulatory dossiers. Simple drag-and-drop interface, submission assembly templates, regular updates.
Efficiently manage and share documents with Ennov Doc. Metadata-based document model, efficient search capabilities, intuitive interface.
Efficiently manage clinical trials with Ennov CTMS. Unified platform, pre-integrated with eTMF and EDC, customizable workflows.
Effortless Regulatory Submission Documentation. Preconfigured document inventory, intuitive interface, efficient search capabilities.
Simplify Clinical Data Collection with Ennov EDC. Configurable edit checks, allowable values library, and pre-integrated with eTMF and CTMS.
The additional load that a clinical activity imposes on patients above that which would be experienced under normal clinical practice. Source: (CIOMS XI: Patient involvement
Burden is defined as the additional load that a risk minimisation activity imposes on (1) patients, (2) carers, (3) the healthcare system including health care
A warning that appears on a prescription drug’s label and is designed to call attention to serious or life-threatening risks. Not all health authorities implement
Learn how master data management impacts regulatory affairs. Explore the importance of RIM and IDMP integration for data quality, compliance.
Effortlessly manage clinical trial documentation with Ennov eTMF. Centralized repository, intelligent automation, and real-time dashboards.
Streamline Your Business Processes with Ennov Process BPMS. Automate, ensure compliance and increase efficiency.
Streamline Training with a Learning Management System. Simplify compliance monitoring, evaluate staff proficiency, automate onboarding.
Ennov will be sponsoring and exhibiting at the RAPS Euro Convergence 2023 conference from May 10-12, 2023 at the Park Inn by Radisson Amsterdam City
A correction to allow for the probability of many events that are independent, named after Carlo Emilio Bonferroni (1892-1960). In statistical significance testing, it allows,
A measured characteristic of either normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic
An analysis involving only two categories (e.g., baseline vs final values, in contrast to analysis of multiple values from continuous measurements, as for a progression
Bayesian confidence propagation neural network (BCPNN) Empirical Bayesian algorithm used for signal detection in spontaneous report databases.Source: (CIOMS VIII: Signal detection 2010)
A theorem in probability named after Reverend Thomas Bayes (1702-1761). It is used to refer to a philosophy of statistics that treats probability statements as
Factors that describe study participants at the beginning of the study (e.g., age, sex, disease severity). In comparison studies, it is importantthat these characteristics be
A statistical method for making comparisons between groups, whiletaking into account different variables measured at the start of atrial. It is a form of multiple
An identified risk associated with the use of medicinal products which requires urgent measures to protect patients. Source: (CIOMS VIII: Signal detection 2010)
A tool that assesses the methodological rigour and transparency in which a guideline is developed. Source: (CIOMS XI: Patient involvement 2022)
The clinical trial industry is constantly evolving, with electronic Trial Master Files (eTMF) becoming increasingly popular among sponsors and CROs. By reducing the need for
In this white paper, we explore the regulatory requirements, processes, and best practices related to creating certified copies of original documents within an eTMF system.
Navigating the complex world of electronic Common Technical Document (eCTD) submissions to the FDA can be a daunting task. Ensuring compliance with FDA regulations and
As a leading software company that provides innovative solutions to the life sciences, healthcare, and other regulated industries, we at Ennov understand the importance of
One of 5 dimensions in the RE-AIM evaluation model (Reach, Efficacy, Adoption, Implementation, Maintenance). Adoption refers to the participation rate and representativeness of both the
A risk minimisation measure which is in addition to the routine risk minimisation activities which apply to all medicinal products in a particular region or
A system for the collection of case safety information as a continuous pre-organized process. Active surveillance can be: Source: (CIOMS DILI 2020)
The degree of risk (likelihood of an adverse event or outcome) that a person or group is prepared to take or considers reasonable. However, what
The environment or community concerned with research, education, and scholarship. Source: (CIOMS XI: Patient involvement 2022)
The number of people in a group who experience an adverse effect divided by the number in that group who could experience that adverse effect.
Ennov’s regulatory and quality offers have registered excellent results, positioning the company as one of the world’s leaders. The orders should enable another year of
As clinical trial complexity increases, life sciences companies must have a technology strategy that supports research, development, and commercial business units. A recent Gartner report,
© 2024 Ennov All rights reserved